Protective Role of (-)-Epicatechin on Trimethylamine-N-Oxide (TMAO)-Induced Cardiac Hypertrophy via SP1/SIRT1/SUMO1 Signaling Pathway
Cardiovascular Toxicology · 2024
DOI: 10.1007/s12012-024-09932-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Toxicology, 2024. Verfasst von Siting Hong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital, Harbin Medical University, No. 23 YouZheng Street, NanGang District, Harbin, 150001, Heilongjian…. Hauptthemen laut MEDLINE: Sirtuin 1, Signal Transduction, Methylamines, Mice, Inbred C57BL. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, the Postdoctoral Research Fund of China, the Support Project for Outstanding Young Talents of the First Affiliated Hospital of Harbin Medical University.
Abstract (Originalsprache)
(-)-Epicatechin (EPI) is beneficial for cardiovascular health. Trimethylamine N-oxide (TMAO), a gut microbe-derived food metabolite, is strongly associated with the risk of cardiovascular diseases. However, the effects and underlying mechanisms of EPI on TMAO-induced cardiac hypertrophy remain unclear. This study aimed to determine whether EPI inhibits TMAO-induced cardiac hypertrophy. Plasma levels of TMAO in control participants and patients with cardiac hypertrophy were measured and analyzed. Male C57BL/6 mice were randomly divided into control group, TMAO group, EPI group and TMAO + EPI group. According to the groups assignments, mice received intraperitoneal (i.p.) injection of normal saline or i.p. injection of TMAO (150 mg/kg/day) for 14 days. The EPI group was given intragastric (i.g.) administration of EPI alone (1 mg/kg/day) for 21 days, and TMAO + EPI group received i.g. administration of EPI for 7 days before starting i.p. injection of TMAO, continuing until the end of the TMAO treatment. Histological analyses of the mice's hearts was accessed by H&E and Masson staining. In vitro, H9c2 cells were induced to hypertrophy by TMAO (10 µM) for 24 h and were pre-treated with or without EPI (10 µM) for 1 h. Protein level of cardiac hypertrophy markers and Sp1/SIRT1/SUMO1 pathway were determined by western blot. The plasma level of TMAO was 2.66 ± 1.59 μmol/L in patients with cardiac hypertrophy and 0.62 ± 0.30 μmol/L in control participants. EPI attenuated TMAO-induced hypertrophy in H9c2 cells. In vivo, TMAO induced cardiac hypertrophy and impaired the cardiac function of mice. Pathological staining showed that TMAO induced cardiac hypertrophy and collagen deposition in mice. EPI treatment improved the cardiac function, inhibited the myocardial hypertrophy induced by TMAO. EPI significantly attenuated the TMAO-induced upregulation of ANP and BNP and the downregulation of SP1, SIRT1 and SUMO1 in vivo and in vitro. EPI may suppress TMAO-induced cardiac hypertrophy by activating the Sp1/SIRT1/SUMO1 signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, First Affiliated Hospital, Harbin Medical University, No. 23 YouZheng Street, NanGang District, Harbin, 150001, Heilongjiang, China.
- The Key Laboratory of Cardiovascular Disease Acousto-Optic Electromagnetic Diagnosis and Treatment in Heilongjiang Province, the First Affiliated Hospital, Harbin Medical University, Harbin, China.
- Department of Pharmacy, First Affiliated Hospital, Harbin Medical University, Harbin, China.
- Department of ECG Room, Xi'an People's Hospital (Xi'an Fourth Hospital), Xi'an, Shaanxi, China.
- Department of Pharmacology (The Key Laboratory of Cardiovascular Research, Ministry of Education) at College of Pharmacy, Harbin Medical University, Harbin, China.
- College of Clinical Medicine, North China University of Science and Technology, Tangshan, Hebei, China.
Förderung
- National Natural Science Foundation of China
- the Postdoctoral Research Fund of China
- the Support Project for Outstanding Young Talents of the First Affiliated Hospital of Harbin Medical University
- the Doctor Funds of the First Affiliated Hospital of Harbin Medical University
Zitieren
APA
Hong, S., Lu, J., Li, J., Luo, Y., Liu, D., Jin, Y., Wang, Z., Wang, Y., Zhang, H., Zhang, X., Li, Y., Zhang, H., Dong, Z., Wang, Z., Lv, L., & Liang, Z. (2024). Protective Role of (-)-Epicatechin on Trimethylamine-N-Oxide (TMAO)-Induced Cardiac Hypertrophy via SP1/SIRT1/SUMO1 Signaling Pathway. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-024-09932-8
Vancouver
Hong S, Lu J, Li J, Luo Y, Liu D, Jin Y, et al. Protective Role of (-)-Epicatechin on Trimethylamine-N-Oxide (TMAO)-Induced Cardiac Hypertrophy via SP1/SIRT1/SUMO1 Signaling Pathway. Cardiovascular Toxicology. 2024. doi:10.1007/s12012-024-09932-8
BibTeX
@article{Hong2024,
author = {Hong, Siting and Lu, Jing and Li, Jiaoyan and Luo, Yingchun and Liu, Dongxue and Jin, Yuanyuan and Wang, Zeng and Wang, Yibo and Zhang, Hao and Zhang, Xin and Li, Yang and Zhang, Haoruo and Dong, Zengxiang and Wang, Zhaojun and Lv, Lin and Liang, Zhaoguang},
title = {Protective Role of (-)-Epicatechin on Trimethylamine-N-Oxide (TMAO)-Induced Cardiac Hypertrophy via SP1/SIRT1/SUMO1 Signaling Pathway},
journal = {Cardiovascular Toxicology},
year = {2024},
doi = {10.1007/s12012-024-09932-8}
}
EUVIMED